European perspective on multiple myeloma treatment strategies: update following recent congresses.

The Oncologist
H LudwigAntonio Palumbo

Abstract

The management of multiple myeloma has undergone profound changes over the recent past as a result of advances in our understanding of the disease biology as well as improvements in treatment and supportive care strategies. Notably, recent years have seen a surge in studies incorporating the novel agents thalidomide, bortezomib, and lenalidomide into treatment for different disease stages and across different patient groups. This article presents an update to a previous review of European treatment practices and is based on discussions during an expert meeting that was convened to review novel agent data published or presented at medical meetings until the end of 2011 and to assess their impact on treatment strategies.

References

Nov 16, 2004·Bone Marrow Transplantation·A FassasB Barlogie
Sep 8, 2005·Expert Opinion on Investigational Drugs·Maureen Haas, Sagar Lonial
Mar 10, 2006·The New England Journal of Medicine·Bart BarlogieJohn Crowley
Jul 29, 2006·Blood·Michel AttalUNKNOWN Inter-Groupe Francophone du Myélome (IFM)
Aug 8, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert Z OrlowskiJean-Luc Harousseau
Dec 21, 2007·Leukemia·A PalumboUNKNOWN International Myeloma Working Group
Aug 30, 2008·The New England Journal of Medicine·Jesús F San MiguelUNKNOWN VISTA Trial Investigators
Mar 11, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andrew SpencerNola Kennedy
Apr 25, 2009·Seminars in Hematology·Efstathios KastritisMeletios A Dimopoulos
May 20, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Cyrille HulinPhilippe Moreau
Sep 23, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michele CavoPatrizia Tosi
Feb 24, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Heinz LudwigBrian Durie
Mar 11, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Nicholas J DickensGareth J Morgan
Mar 23, 2010·Cancer Chemotherapy and Pharmacology·Donna E ReeceA Keith Stewart
Jun 3, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Pierre WijermansUNKNOWN Dutch-Belgium Cooperative Group HOVON
Jun 19, 2010·International Journal of Hematology·Shinsuke IidaTomomitsu Hotta
Jul 21, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hervé Avet-LoiseauJean-Luc Harousseau
Aug 11, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Henk LokhorstUNKNOWN International Myeloma Working Group
Sep 25, 2010·Cancer Treatment Reviews·Niels W C J van de DonkAntonio Palumbo
Oct 12, 2010·The Lancet Oncology·Michel DelforgePieter Sonneveld
Oct 15, 2010·European Journal of Haematology·Meletios A DimopoulosKenneth C Anderson
Oct 20, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Meletios A DimopoulosJésus San Miguel

❮ Previous
Next ❯

Citations

Oct 1, 2013·Current Hematologic Malignancy Reports·Tommasina Guglielmelli, Antonio Palumbo
Jan 30, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Ruben NiesvizkyMaureen E Lane
Mar 13, 2013·Expert Review of Anticancer Therapy·Ali McBride, Patricia Y Ryan
Jan 30, 2014·Expert Review of Hematology·Philip L McCarthySergio Giralt
Oct 19, 2013·Seminars in Oncology·Michele CavoE Zamagni
Jan 8, 2014·Artificial Organs·Detlef H KrieterHorst-Dieter Lemke
Dec 30, 2014·Lancet·Christoph RölligMartin Bornhäuser
Jan 23, 2015·Wiener klinische Wochenschrift·Wolfgang LammJohannes Drach
Nov 26, 2014·Nature Reviews. Clinical Oncology·Meletios A DimopoulosKenneth C Anderson
Jun 14, 2016·British Journal of Haematology·Marc S RaabKwee Yong
Jun 10, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ruben NiesvizkyJames Reeves
Jul 27, 2014·The Oncologist·Heinz LudwigAntonio Palumbo
Jun 22, 2018·Oncology Letters·Ying Yu LiangRudolf Oehler

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.